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OBJECTIVES: To derive Australian utility values for different
health states associated with a new treatment regimen used as
induction chemotherapy before concurrent chemoradiation for
patients with locally advanced squamous cell carcinoma of the
head and neck (SCCHN). METHODS: As head and neck
cancer includes over 30 speciﬁc sites of cancer, for simplicity,
the study focused on oropharyngeal cancer. This reduced the
need to present multiple attributes in each scenario, and
reduced complexity of the study with the aim of preventing
cognitive overload among respondents. 86 participants were
recruited by an independent research company. They ranged
from 18–77 years (mean age 44 years). Participants were pre-
sented information about locally advanced SCCHN, as well as
cancer of the oropharynx and its treatment. Participants were
then presented with 10 health states describing locally
advanced cancer of the oropharynx and its chemotherapy treat-
ment and were asked to value these using a standard gamble
technique. RESULTS: The results showed that participants suc-
cessfully valued the health states, applying values derived for
the main four health states (baseline, responding, non-
responding and disease progression) and their varying toxicity
levels in a logical sequence. Utility values ranged from 0.67
(SD = 0.24) for treatment response, 0.65 (SD = 0.24) at base-
line, 0.60 (SD = 0.27) for non-response, and 0.48 (SD = 0.23)
for a patient experiencing disease progression. When mild,
moderate and severe toxicities were added, face validity of
results showed the standard gamble instrument was sensitive to
these differences. CONCLUSIONS: Within the broad term
‘head and neck cancer’, tumours are biologically similar as are
some of the associated symptoms of disease. As such, it could
be expected that the same incremental differences in utilities
could be derived for health state scenarios using the same treat-
ment for SCCHN but arising in alternate tumour sites such as
the hypopharynx, oral cavity or larynx.
PCN78
QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC
BREAST CANCER (MBC) INTREATMENT WITH PLACITAXEL
WITH/WITHOUT BEVACIZUMAB, RELATED WITH
TREATMENT RESPONSE (REMISSION AND PROGRESSION)
Tenorio C1,Vargas J2
1Instituto Nacional de Cancerología, Mexico, DF, Mexico,
2Econopharma Consulting SA de CV, Mexico, DF, Mexico
OBJECTIVES: To perform a QoL evaluation in patients with
mBC in treatment with chemotherapy with/without bevaci-
zumab according with treatment response. METHODS: We
included 48 patients with mBC in two groups, 28 without
disease progression (NP) median age 55.19 years (51.2–59.18)
and 5.6 years (3.07–8.13) of disease evolution; and 20 with
disease progression (DP) median age 57.7 years (50.9–64.5)
and 3.74 years (2.48–4.99) of evolution. We applied to both
groups the Functional Assessment of Cancer Treatment—
Biological Response Modiﬁer questionnaire. The dimension
between the ﬁve answers categories (Not at all, A little bit,
Some-what, Quite a bit, Very much) was quantiﬁed using the
Karnofsky scale in order to construct a QoL index. A one year
QoL evaluation was done with a simulation using a Markov
Model, the model included three health status: remission,
relapse and dead. The probability of progression and dead was
obtained of the data reported with the use of Placitaxel w/wo
Bevacizumab (Miller K. 2007) assuming an exponential behav-
ior. RESULTS: The 78.2% (75%–82%) of patients with NP
reported a good or very good status, compared with 23.6%
(14%–34%) of patients with DP. The global QoL reported by
patients with NP was 80.66% (78.99%–82.34%) signiﬁcantly
greater than 66.97% (66.97%–69.69%) obtained form patients
with DP (Mann-Whitney < 0.0001). The QoL results showed
differences in the use of chemotherapy, there was a greater
improve in QoL mBC patients with Paclitaxel + Bevacizumab
than with Placitaxel alone: 0.77 vs. 0.745 p = 0.017. CON-
CLUSIONS: The QoL level reported by patients with mBC is
determined by the presence or absence of disease progression,
better QoL no disease progression. With these data, it is
possible that the use of Paclitaxel + Bevacizumab, improves
QoL and might be, it’ll related with less social and familiar
disturbances.
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OBJECTIVES: To review and describe HRQoL measures devel-
oped or applied in kidney cancer, hepatocellular carcinoma and
leukemia patients under drug therapy. METHODS: A compre-
hensive search in PubMed was conducted to identify studies
assessing quality of life in these cancer patients. Based on the
review of the full publications, studies that were not speciﬁc to
HRQoL in patients treated with drugs were removed. RESULTS:
A total of 32 studies including four studies identiﬁed through
reference list checking and 21 HRQoL instruments were identi-
ﬁed. There were six generic instruments (e.g. EQ-5D or the
PedsQL), ﬁve disease-speciﬁc instruments (e.g. EORTC QLQ
C-30, FACT-G, FACT-Hep) and ten domain-speciﬁc instruments
(e.g. FACT-BRM, FACT-An). Most studies chose the EORTC
QLQ C-30 and the FACT-G or some FACIT subscales that were
constructed to complement the FACT-G, like the FACT-Hep and
the FACT-BRM. There were also some symptom-speciﬁc instru-
ments used in the identiﬁed literature, such as the FACT-An, the
FACT-FKSI, or the BFI. For kidney cancer and leukemia patients,
no disease-speciﬁc instruments could be found. Wilms’ tumor
and acute lymphocytic leukemia (ALL) are the most common
types of cancer in children. The development of pediatric cancer-
speciﬁc HRQoL measures poses a challenge; proxy rating is
extensively applied when assessing the quality of life in children.
CONCLUSIONS: Little research has been conducted in HRQoL
research in the selected indications. To dilute this statement to a
certain extent one could say that at least no overall standards
could be observed. When assessing the quality of life in these
three cancers looking at patients treated with drugs, the use of
the EORTC QLQ C-30 and the FACT-G questionnaire is empha-
sized. Additionally, some subscales of the FACIT (being a part of
the FACT-G) could be incorporated into research. Furthermore
symptom-speciﬁc instruments can also be used as a source of
reference.
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